Can circulating TMAO directly measure gut microbial TMA production from choline and carnitine?

Dietary choline and carnitine are established substrates for gut microbial trimethylamine (TMA) production, but plasma trimethylamine N-oxide (TMAO) is a downstream composite biomarker—not a direct measure of that microbial flux.

Microbial pathways

• Choline: Anaerobic bacteria use the CutC/CutD system. CutD activates the glycyl-radical enzyme CutC, which cleaves choline into TMA and acetaldehyde.
• Carnitine: Several routes operate. Some bacteria use oxygen-dependent CntA/CntB for direct L-carnitine-to-TMA conversion. In the anaerobic gut, a physiologically important pathway converts L-carnitine to γ-butyrobetaine (γBB), followed by gbu/bbu-associated microbial conversion of γBB to TMA.
• Human stable-isotope feeding studies support these pathways: labeled choline/phosphatidylcholine or carnitine yields labeled downstream TMAO, with marked suppression during broad-spectrum antibiotic exposure and recovery after antibiotics are withdrawn.

Why circulating TMAO cannot quantify microbial TMA production

• TMA must first be absorbed and oxidized, predominantly by hepatic flavin-containing monooxygenase 3 (FMO3), to become circulating TMAO. Thus, plasma TMAO lies downstream of microbial activity.
• A single TMAO concentration also reflects recent dietary precursor exposure, preformed TMAO from fish/seafood, FMO3 activity, distribution, and—especially—renal clearance.
• Reduced kidney function can substantially raise TMAO through impaired excretion without a proportional increase in intestinal microbial TMA generation. Conversely, variation in FMO3 activity can alter TMAO formation from a given TMA exposure.

Bottom line

• The claim is supported: gut microbes convert dietary choline and carnitine to TMA through distinct pathways, but circulating TMAO cannot directly quantify the microbial production step in an individual. Interpreting TMAO requires dietary, kidney-function, hepatic-metabolic, and microbiome context.